Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Icodextrin: overview of clinical experience

E Peers1, R Gokal

  • 1ML Laboratories plc, St. Albans, Manchester, England.

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome of pregnancy following renal transplantation.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2004
Same author

Bacillus circulans peritonitis in a patient treated with CAPD.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2004
Same author

End-stage renal disease in Indo-Asians in the North-West of England.

QJM : monthly journal of the Association of Physicians·2003
Same author

Treatment of infections in peritoneal dialysis.

Contributions to nephrology·2003
Same author

Peritoneal dialysis as the first-choice treatment.

Contributions to nephrology·2003
Same author

Side-effects of antituberculosis drug treatment in patients with chronic renal failure.

The European respiratory journal·2002

Icodextrin offers sustained ultrafiltration for peritoneal dialysis patients, providing a glucose alternative. This osmotic agent has a decade of clinical use and potential for intraperitoneal drug delivery.

Area of Science:

  • Nephrology
  • Biomedical Engineering

Background:

  • Peritoneal dialysis is a key treatment for end-stage renal failure.
  • Glucose-based osmotic agents are standard but have limitations.
  • Icodextrin offers an alternative osmotic agent for peritoneal dialysis solutions.

Purpose of the Study:

  • To review clinical studies and experience with icodextrin.
  • To evaluate icodextrin's efficacy in peritoneal dialysis.
  • To explore icodextrin's potential as an intraperitoneal vehicle.

Main Methods:

  • Literature review of peer-reviewed articles and scientific meeting abstracts.
  • Inclusion of data from compassionate use programs.
  • Synthesis of findings from approximately 10-20 studies.

Related Experiment Videos

Main Results:

  • Over ten years of clinical experience with icodextrin in CAPD and APD.
  • Sustained ultrafiltration achieved with icodextrin during long peritoneal dialysis dwells.
  • Icodextrin functions via colloid osmosis and is iso-osmolar.

Conclusions:

  • Icodextrin is the first viable alternative osmotic agent to glucose for peritoneal dialysis.
  • Icodextrin demonstrates sustained efficacy over extended use.
  • Potential applications include intraperitoneal drug delivery.